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Antibodies that block PD-1/PD-L1 interactions have
shown efficacy against both lung and skin cancers in
early-stage clinical trials, and may also be effective in
other tumor types, particularly bladder tumors. PD-L1
expression has been previously reported to correlate
with high-grade tumors, a high recurrence rate, and
reduced survival rate in patients with bladder cancer.
These findings and the high frequency of somatic muta-
tions found in bladder tumors indicate that bladder can-
cer patients may respond well to anti-PD-L1 therapy.
Both murine (MB49, MBT-2) and human (J82, T24,
TCCSUP) bladder cancer cell lines constitutively express
PD-L1 as determined by flow cytometry. As expected, in
vitro IFN-g addition up-regulated PD-L1 expression
levels on each of those tumor cells. A human IgG1 anti-
PD-L1 antibody, MSB0010718C, induced ADCC activity
in vitro against all three human bladder cancer cell lines
following treatment with IFN-g. In initial in vivo murine
studies, the growth of s.c. MB49 tumors in syngeneic
mice was significantly delayed following three i.p. injec-
tions of 400 µg of the MSB0010718C anti-PD-L1 anti-
body. An orthotopic bladder model consisting of the
MB49 cells tagged with luciferase (MB49-luc) was also
used to evaluate the antitumor efficacy of the anti-PD-
L1 antibody. MB49-luc cells were instilled intravesically
(bladder) in B6 mice. Beginning at 7 or 10 days post-
instillation, three i.p. injections of the anti-PD-L1 anti-
body substantially reduced tumor volumes, as determined
by intravital imaging, leading to long-term tumor-free sur-
vival for 40-60% of the treated mice. While initial immune
cell subset depletion studies implicated both CD4+ and
CD8+ T cells, continuing efforts will further define the cel-
lular mechanisms responsible for the antitumor effects of
the anti-PD-L1 antibody. Taken together, these results
suggest that MSB0010718C therapy might be used to acti-
vate both innate and adaptive immune mechanisms to
treat PD-L1-expressing bladder tumors. Furthermore, the
MB49 tumor model can be used to evaluate the combined
effects of anti-PD-L1 and other therapeutic agents, parti-
cularly ones that induce IFN-g production and tumor
PD-L1 up-regulation. MSB0010718C is currently being
evaluated in a Phase I clinical trial (NCT01772004).
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